Learn about the Know Now BRAF Testing Program and request BRAF testing for your patients with stage III or stage IV melanoma  
 
     
 
  Understanding your patient's BRAF status today may help you make a treatment decision tomorrow  
 
 
  Your Novartis representative  
 
{{userPhoto}}
 
{{userName}}
{{user.Phone}}
 
     
 
  Dear [Drop-down:"Dr", "Mr", "Mrs", "Ms"] [Last Name]:  
 
 
[Opening/introduction drop-down:
 
1.  Thank you for taking the time to meet with me to discuss the Know Now BRAF Testing Program. You requested information about this and I am following up with relevant material.
 
2.  I'm sorry we missed each other when I stopped by your office. However, below is information about the Know Now BRAF Testing Program for your review.
 
3.  It's been a while since our last meeting, so I am sharing information about the Know Now BRAF Testing Program that may be of interest to you.
 
4.  Hello. I am your Novartis representative. I would like to share information with you about the Know Now BRAF Testing Program that may be useful for you, your staff, and your patients with stage III or stage IV melanoma.
 
5.  Below is additional information regarding our recent discussion about the Know Now BRAF Testing Program.
 
6.  I am following up with you regarding information I left with you about the Know Now BRAF Testing Program.
 
7.  It was good speaking with you recently. I am providing you with additional information about the Know Now BRAF Testing Program, as discussed.
 
8.  It was a pleasure speaking with you. As requested, I'm following up with further information about the Know Now BRAF Testing Program.]
 
 
     
 
  KNOW YOUR PATIENT'S BRAF MUTATION STATUS BEFORE YOU MAKE YOUR TREATMENT DECISION  
 
  BRAF mutation status is an important prognostic factor when choosing a first-line therapy for your patients with stage IIIB/C or stage IV melanoma. 1,2  
 
 
 
  NOVARTIS UNDERSTANDS THE IMPORTANCE OF
TESTING PATIENTS WITH ADVANCED MELANOMA		  
 
 
 
  NOVARTIS IS NOW OFFERING BRAF TESTING FOR ALL OF YOUR PATIENTS WITH STAGE III OR STAGE IV MELANOMA*  
 
  The Know Now BRAF Testing Program will use the THxID ® -BRAF kit to test for V600E/K mutations, and the results you need will be available approximately 48 hours after the Quest lab receives the BRAF Test Request Form, the pathology report, and the pathology sample.  
 
     
 
{{insertEmailFragments[2,2]}}
     
 
 
* C43, melanoma; C80, malignant neoplasm, unspecified; Z85, personal history of malignant neoplasm. The THxID-BRAF kit is a registered trademark of bioMérieux, Inc.
 
 
     
 
 
 
[Closing Drop-down:
 
1.  Should you like to follow up, I would be happy to share more information with you about the Know Now BRAF Testing Program. Please feel free to contact me.
 
2.  Because we haven't met recently, I invite you to contact me to arrange a time when we can discuss additional information about the Know Now BRAF Testing Program.
 
3.  Thank you for reviewing this information about the Know Now BRAF Testing Program. I hope you found it useful. Please do not hesitate to contact me if you have any questions about the information provided or would like additional materials.
 
4.  Because you requested this information, I wanted to answer any questions you may have. Please don't hesitate to contact me if there is anything else you need.
 
5.  If you have any questions, please contact me for additional information.
 
6.  Should you require more information, it would be my pleasure to speak with you. Please let me know when it would be a good time to further discuss the Know Now BRAF Testing Program.]
 
 
  [Drop-down: "Sincerely", "Best regards", "Thank you",]
[Name]
[Phone]		  
 
     
 
  References: 1. Houben R, Becker JC, Kappel A, et al. Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis. J Carcinog. 2004;3:6. doi:10.1186/1477-3163-3-6. 2. Barbour AP, Tang YH, Armour N, et al. BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: implications for melanoma staging and adjuvant therapy. Eur J Cancer. 2014;50(15):2668-2676.  
 
     
 
  If you have any questions concerning e-mail or marketing communications from Novartis Pharmaceuticals Corporation, please call 1-888-NOW-NOVA (1-888-669-6682), Monday to Friday, 8:30 AM to 5:00 PM ET.  
 
  If you prefer not to receive e-mail communications about melanoma in this channel, please click here.  
 
  For more information, please visit the Novartis Privacy Policy.  
 
     
 
Advertisement